Europe Periodontal Therapeutics Market Tips You Will Read

Europe is expected to hold a market revenue share of 29% in the year 2020, growing with a CAGR of 8.6% during the forecast period.

A significant rise in diabetes among the European population has led to increasing demand for periodontal therapeutics in the region. According to the World Health Organization, dental caries affects 20-90 percent of children under the age of six in Europe. Periodontal disease affects 5–20 percent of middle-aged (35–44 year) adults in Europe, and roughly 40 percent of the elderly

Over 50% of the European population may suffer from some form of periodontitis and over 10% have severe disease, with prevalence increasing to 70-85% of the population aged 60- 65 years of age

UK, Germany, and France held market revenue shares of 23%, 22%, and 17% respectively, in the year 2020

Germany's periodontal therapeutics market value is likely to reach USD 80.8 million in 2028, from its recorded value of USD 40.7 million in 2020, growing with a CAGR of 9.3% during the forecast period. Around half the adult population in Germany is affected by periodontal disease and it is the second most common chronic ailment after caries. For over 40-year-olds, even more, teeth are lost by gum disease than by caries. In Germany, almost 60% of adults suffer from tooth disease. A maximum of 3% of expenditure on dental care is used for periodontal therapies. Hence, the increasing number of people suffering from periodontal disease is expected to drive the market growth in this country

Moreover, favorable reimbursement and insurance policies in the country are expected to positively influence the market growth. If periodontitis is medically required, statutory health insurance in Germany will cover the costs of systematic treatment

France held a market revenue share of 16.8% in the year 2020. In France, 80% of adults ages 35 to 44 have some form of gum disease. 17% of France’s population, equating to 10 million people, suffer from periodontitis. Hence, the market value for periodontal therapeutics in France is expected to grow with a CAGR of 8.2% during the forecast period

Italy is another key country contributing to the growth of Europe's periodontal therapeutics market. Periodontal disease (PD) is one of the most prevalent chronic diseases in the world and the Italian population. Periodontal disorders affected around 15.8 thousand Italians out of a population of 100 million in 2019

France held a market revenue share of 16.8% in the year 2020. In France, 80% of adults ages 35 to 44 have some form of gum disease. 17% of France’s population, equating to 10 million people, suffer from periodontitis. Hence, the market value for periodontal therapeutics in France is expected to grow with a CAGR of 8.2% during the forecast period

Italy is another key country contributing to the growth of Europe's periodontal therapeutics market. Periodontal disease (PD) is one of the most prevalent chronic diseases in the world and the Italian population. Periodontal disorders affected around 15.8 thousand Italians out of a population of 100 million in 2019

Spain's periodontal therapeutics market is expected to grow with a CAGR of 7.7% during the forecast period, reaching USD 39 million in 2028, from its recorded value of USD 21.9 million in 2020. According to the last oral health survey of the Spanish population in 2017, between 24% and 37% of Spaniards aged over 35 years have periodontitis and 6% to 10% of the adult population have deep periodontal pockets

In 2020, the population aged 65 years and above in Spain was 20 %. The population aged 65 years and above in Spain increased from 9.8 % in 1971 to 20 % in 2020 growing at an average annual rate of 1.47%. By 2050, up to 30% of Spain's population will be over 65, with the number of people aged 80 and up expected to reach four million. The increasing elderly population pool is expected to drive the market growth in this country

Moreover, the prevalence of hypertension in Spain is high, and a considerable percentage of hypertensive patients have still not been diagnosed. Adults with periodontitis may be significantly more likely than those with healthy gums to have high blood pressure, according to a study published in March 2021

However, in the United Kingdom and France, not all periodontitis treatment is covered by the public health system, and the patient pays for the remainder. The majority of periodontal therapy in Spain and Italy is paid for by the patient or through private insurance. Treatment for periodontitis is nearly unaffordable for low-income families, thus restricting the market growth to a certain extent.

About Us:

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within less than a year, we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com